Advisor Group Holdings Inc. acquired a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 7,897 shares of the company’s stock, valued at approximately $72,000. Advisor Group Holdings Inc. owned 0.05% of OptimizeRx at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Citigroup Inc. lifted its position in OptimizeRx by 304.2% during the 4th quarter. Citigroup Inc. now owns 2,765 shares of the company’s stock worth $28,000 after acquiring an additional 2,081 shares during the period. BNP Paribas Arbitrage SA lifted its position in OptimizeRx by 115.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,279 shares of the company’s stock worth $39,000 after acquiring an additional 2,290 shares during the period. Eudaimonia Partners LLC acquired a new stake in OptimizeRx during the 1st quarter worth approximately $41,000. UBS Group AG lifted its position in OptimizeRx by 34.9% during the 4th quarter. UBS Group AG now owns 17,000 shares of the company’s stock worth $175,000 after acquiring an additional 4,397 shares during the period. Finally, Wells Fargo & Company MN lifted its position in OptimizeRx by 31.6% during the 1st quarter. Wells Fargo & Company MN now owns 33,066 shares of the company’s stock worth $299,000 after acquiring an additional 7,934 shares during the period. 54.62% of the stock is owned by institutional investors.
NASDAQ OPRX opened at $14.15 on Friday. OptimizeRx Co. has a 1-year low of $6.50 and a 1-year high of $17.24. The company has a market capitalization of $207.30 million, a P/E ratio of -38.24 and a beta of 0.31. The business has a 50 day moving average price of $13.77 and a 200 day moving average price of $10.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.88 and a quick ratio of 2.88.
OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The firm had revenue of $7.59 million during the quarter, compared to analysts’ expectations of $7.10 million. OptimizeRx had a negative net margin of 19.86% and a negative return on equity of 11.18%. On average, research analysts expect that OptimizeRx Co. will post -0.29 earnings per share for the current fiscal year.
Several analysts have recently commented on the company. B. Riley raised their price target on OptimizeRx from $18.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. ValuEngine cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a report on Friday, April 17th. Zacks Investment Research raised OptimizeRx from a “sell” rating to a “hold” rating in a report on Friday, May 29th. Lake Street Capital raised their price target on OptimizeRx from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, June 8th. Finally, TheStreet raised OptimizeRx from a “d+” rating to a “c-” rating in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $18.33.
In other OptimizeRx news, CFO Douglas P. Baker sold 6,667 shares of the firm’s stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $15.00, for a total transaction of $100,005.00. Following the completion of the transaction, the chief financial officer now owns 82,671 shares of the company’s stock, valued at $1,240,065. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.40% of the company’s stock.
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Recommended Story: How do buyers and sellers choose a strike price?
Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX).
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.